Prostate-specific antigen testing for early diagnosis of prostate cancer: Formulation of guidelines

Urology

Volumn 54, Issue 5, 1999, Pages 780-786

  Carter, H Ballentine ^a   Pearson, Jay D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

AGE FACTORS; CLINICAL PROTOCOLS; HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 0032702528     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00271-X     Document Type: Review

References (35)

1. Barry M.J., Fleming C., Coley C.M., et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I framing the debate . Urology. 46:1995;2-13.
2. Kramer B.S., Brown M.L., Prorok P.C., et al. Prostate cancer screening what we know and what we need to know . Ann Intern Med. 119:1993;914-923.
3. Coley C.M., Barry M.J., Fleming C., et al. Early detection of prostate cancer. Part I: prior probability and effectiveness of tests . Ann Intern Med. 126:1997;394-406.
4. Middleton R.G. Prostate cancer are we screening and treating too much? Ann Intern Med. 126:1997;465-467.
5. Stephenson R.A., Smart C.R., Mineau G.P., et al. The fall in incidence of prostate carcinoma on the downside of a prostate specific antigen induced peak in incidence-data from the Utah Cancer Registry . Cancer. 77:1996;1342-1348.
6. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA. 270:1993;948-954.
7. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 273:1995;289-294.
8. Carter H.B., Pearson J.D. PSA and the natural course of prostate cancer. Schroder F.H. Recent Advances in Prostate Cancer and BPH. 1997;187-193 Parthenon Publishing Group, New York.
9. Jacobsen S.J., Katusic S.K., Bergstralh E.J., et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 274:1995;1445-1449.
10. Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer. 54:1993;563-570.
11. Stephenson R.A. Population-based prostate cancer trends in the PSA era data from the Surveillance, Epidemiology, and End Results (SEER) program . Monogr Urol. 19:1998;3-19.
12. Cramer D.W. The role of cervical cytology in the declining morbidity and mortality of cervical cancer. Cancer. 34:1974;2018-2027.
13. Wingo P.A., Ries L.A.G., Rosenberg H.M., et al. Cancer incidence and mortality, 1973-1995. A report card for the U.S. Cancer. 82:1998;1197-1207.
14. Harlin L., Brawley O., Pommerenke F., et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 13:1995;93-100.
15. Roberts R.O., Bergstralh E.J., Katusic S.K., et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 161:1999;529-533.
16. Gilliland F., Becker T.M., Smith A., et al. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev. 3:1994;105-111.
17. Mettlin C., Murphy G.P., Menck H. Trends in treatment of localized prostate cancer by radical prostatectomy observations from the Commission on Cancer National Cancer Database, 1985-1990 . Urology. 43:1994;488-492.
18. Jacobsen S.J., Bergstralh E.J., Katusic S.K., et al. Screening digital rectal examination and prostate cancer mortality a population-based case-control study . Urology. 52:1998;173-179.
19. von Eschenbach A., Ho R., Murphy G.P., et al. American Cancer Society guidelines for the early detection of prostate cancer. Cancer. 80:1997;1805-1807.
20. Coley C.M., Barry M.J., Fleming C., et al. Clinical guideline part III screening for prostate cancer . Ann Intern Med. 126:1997;480-484.
21. Carter H.B., Epstein J.I., Partin A.W. The influence of age and prostate specific antigen on the chance of curable prostate cancer among men with non-palpable disease. Urology. 53:1999;126-130.
22. Shun-Zhang Y., Miller A.B., Sherman G.J. Optimising the age, number of tests, and test interval for cervical screening in Canada. J Epidemiol Comm Health. 36:1982;1-10.
23. Ross K.S., Pearson J.D., Guess H.A., et al. Rational PSA screening strategies for prostate cancer computer simulations of age ranges, PSA cutoffs, and testing intervals (abstract) . J Urol. 161:1999;210.
24. Shock NW, Greulich RC, Andres R, et al: Normal human aging: the Baltimore Longitudinal Study of Aging. NIH publication No. 84-2450. Washington, DC, United States Government Printing Office, November 1984.
25. Screening for squamous cervical cancer duration of low risk after negative results of cervical cytology and its implication for screening policies . BMJ. 293:1986;659-664.
26. Eddy D.M. Screening for cervical cancer. Ann Intern Med. 113:1990;214-226.
27. Carter H.B., Epstein J.I., Chan D.W., et al. Recommended prostate-specific antigen testing intervals for detection of curable prostate cancer. JAMA. 277:1997;1456-1460.
28. Smith D.S., Catalona W.J., Herschman J.D. Longitudinal screening for prostate cancer with prostate specific antigen. JAMA. 276:1996;1309-1315.
29. Leewansangtong S., Crawford E.D., Gordon S.G., et al. Longitudinal follow up from Prostate Cancer Awareness Week (PCAW) screening intervals (abstract) . J Urol. 159:1998;177.
30. Albertsen P.C., Hanley J.A., Gleason D.F., et al. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 280:1998;975-980.
31. Lu-Yao G.L., Albertsen P., Warren J., et al. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy - a population-based study. Urology. 54:1999;301-307.
32. Ventura S.J., Peters K.D., Martin J.A., et al. Births and deaths United States, 1996 . Mon Vital Stat Rep. 46:1997;1-40.
33. Health Care Financing Administration, Bureau of Data Management and Strategy, 1998.
34. Carter HB, Landis PK, Metter EJ, et al: Prostate specific antigen (PSA) testing of older men. J Natl Cancer Inst (in press).
35. Stephenson R.A., Stanford J.L. Population-based prostate cancer trends in the United States patterns of change in the era of prostate-specific antigen . World J Urol. 5:1997;331-335.